Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Nivolumab-based chemoradiotherapy versus durvalumab after chemoradiotherapy in unresectable stage III non-small cell lung cancer
NL-OMON52857Phase 3Recruiting
- Sponsor
- Bristol Myers Squibb
- Start
- Feb 2021
- Modality
- PD-1/PD-L1 Inhibitors → Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of nivolumab, ipilimumab and durvalumab in non-small cell lung cancer (NSCLC) and bronchial carcinoma (3 arms), sponsored by Bristol Myers Squibb. Primary endpoint: Progression-free survival. Started Feb 2021; status: recruiting.
02
Drugs
03
Conditions
non-small cell lung cancer (NSCLC)bronchial carcinoma
Beyond the preview
Go deeper on NL-OMON52857.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON52857.